Secukinumab for the treatment of SAM syndrome associated with desmoglein-1 deficiency
- PMID: 33205394
- DOI: 10.1111/bjd.19684
Secukinumab for the treatment of SAM syndrome associated with desmoglein-1 deficiency
References
-
- Samuelov L, Sarig O, Harmon RM et al. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting. Nat Genet 2013; 45:1244-8.
-
- Taiber S, Samuelov L, Mohamad J et al. SAM syndrome is characterized by extensive phenotypic heterogeneity. Exp Dermatol 2018; 27:787-90.
-
- Has C, Jakob T, He Y et al. Loss of desmoglein 1 associated with palmoplantar keratoderma, dermatitis and multiple allergies. Br J Dermatol 2015; 172:257-61.
-
- McAleer MA, Pohler E, Smith FJD et al. Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin. J Allergy Clin Immunol 2015; 136:1268-76.
-
- Hernández-Martín A, Kennedy-Batalla R, Cañedo E et al. Imbalance in T-Helper 17 Cells and targeted therapy in an infant with SAM-like syndrome. N Engl J Med 2019; 381:2176-8.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources